The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine



Status:Recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:11/8/2018
Start Date:September 14, 2018
End Date:April 2019
Contact:Cheryl Chen
Email:cechen@neurocrine.com
Phone:858-617-7744

Use our guide to learn which trials are right for you!

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the
potential for clinical dependence and withdrawal symptoms associated with valbenazine.


Inclusion Criteria:

1. Subjects of childbearing potential must agree to use hormonal or two forms of
nonhormonal contraception (dual contraception) consistently during the screening,
treatment, and follow-up periods of the study.

2. Have one of the following clinical diagnoses for at least 3 months before screening:
Schizophrenia, Schizoaffective Disorder, or Mood Disorder

3. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months before
screening.

4. Be on stable doses if using maintenance medication(s) for schizophrenia or
schizoaffective disorder, or mood disorder. Subjects with bipolar disorder must be on
stable doses of a mood stabilizer.

5. Be in general good health.

6. Have adequate hearing, vision, and language skills to perform the procedures specified
in the protocol.

Exclusion Criteria:

1. Have an active, clinically significant unstable medical condition within 1 month
before screening.

2. Have a known history of substance (drug) dependence, or substance or alcohol abuse.

3. Have a significant risk of suicidal or violent behavior.

4. Have a known history of neuroleptic malignant syndrome.

5. Have a known history of long QT syndrome or cardiac arrhythmia.

6. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).

7. Have ever taken valbenazine (INGREZZA or NBI-98854) or participated in a valbenazine
clinical study.

8. Have received an investigational drug within 30 days before screening or plan to use
an investigational drug (other than NBI-98854) during the study.

9. Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.

10. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors (eg,
tetrabenazine, deutetrabenazine).

11. Are currently pregnant or breastfeeding.

12. Have HIV or hepatitis B.
We found this trial at
14
sites
Anaheim, California 92805
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Beechwood, Ohio 44122
?
mi
from
Beechwood, OH
Click here to add this to my saved trials
DeSoto, Texas 75115
?
mi
from
DeSoto, TX
Click here to add this to my saved trials
Glendale, California 91206
?
mi
from
Glendale, CA
Click here to add this to my saved trials
Hialeah, Florida 33012
?
mi
from
Hialeah, FL
Click here to add this to my saved trials
Honolulu, Hawaii 96817
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Irving, Texas 75062
?
mi
from
Irving, TX
Click here to add this to my saved trials
Norwalk, California 90650
?
mi
from
Norwalk, CA
Click here to add this to my saved trials
Oceanside, California 92056
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
San Bernardino, California 92108
?
mi
from
San Bernardino, CA
Click here to add this to my saved trials
San Juan, 00926
?
mi
from
San Juan,
Click here to add this to my saved trials
Scranton, Pennsylvania 18503
?
mi
from
Scranton, PA
Click here to add this to my saved trials